[Fundamental and clinical studies of intravenous drip infusion of micronomicin in respiratory tract infection].
A study was carried out with the aminoglycoside antibiotic micronomicin (MCR) to determine its clinical efficacy in respiratory infections on the one hand and its serum levels on the other. MCR was administered in single dose of 60 mg twice daily by intravenous drip infusion over 1 hour to 5 patients with infections aggravation of chronic bronchitis and 3 with pneumonia. Of the total of 8 patients treated, 3 had remarkable and 4 had good responses with a response rate of 87.5%, while 1 has no benefit. Adverse effects on the clinical picture or on laboratory test results were not observed. The peak serum concentration of MCR after a 1.5 hours drip infusion of 90 mg was 7.74 micrograms/ml. In view of the risk of adverse effects, the serum concentration lay on appropriate levels. It is expected therefore that the intravenous drip infusion of MCR will be of particular interest in the treatment of relapse of chronic bronchitis and pneumonia.
D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D000900:Anti-Bacterial Agents; D004341:Drug Evaluation; D005260:Female; D005839:Gentamicins; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; C037545:micronomicin